Mobile website
Basic Research
Endothelial progenitor cells carrying hIFN-γ enhances efficacy of cancer maintenance therapy after chemotherapy
- Article
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
Abstract:
Objective:To observe the efficacy of endothelial progenitor cells carrying hIFN-γ (EPCs-hIFN-γ) in cancer maintenance therapy after chemotherapy. Methods: MTT was used to examine the inhibitory effects of hIFN-γ and/or C225 against colorectal cancer LoVo cells after treatment with CPT-11. The in vivo inhibitory effects of EPCs-hIFN-γ and/or C225 on LoVo tumors and their effects on survival of LoVo tumor-bearing nude mice were investigated after mice had been treated with CPT-11. Results: In vitro, hIFN-γ and/or C225 further inhibited the growth of cancer cells after CPT-11 treatment. In vivo, after 50 mg/kg CPT-11 treatment, EPCs-hIFN-γ，C225 and EPCs-hIFN-γ+C225 inhibited the growth of tumors in LoVo tumor-bearing nude mice (mean tumor volumes: \[2024.28±1048.40\] mm3 vs \[764.94±720.14\], \[233.85±186.97\], \[186.95±133.43\], \[163.9±173.39\] mm3; P＜0.05). EPCs-hIFN-γ, C225 and EPCs-hIFN-γ+C225 treatment also increased the survival of tumor-bearing mice (median survival: 34.2 d vs 39.4, 445, 48.5, 51.3 d; P<0.05 or P<0.01). Conclusion: EPC-hIFN-γ can inhibit the tumor growth and prolong the survival of tumor-bearing mice in cancer maintenance therapy after chemotherapy.
Keywords:
colorectal neoplasmas, hIFN-γ, endothelial progenitor cell, immunotherapy
Project Supported:
Project supported by “the 11th Five-year Plan” of Key Science and Technology Foundation of PLA（No. 06G140）
